- Record: found
- Abstract: found
- Article: not found
The effects of ranibizumab (Lucentis) on retinal function in isolated perfused vertebrate retina.
M Lüke
1 ,
K Januschowski ,
J Lüke ,
S Peters ,
N Wirtz ,
E Yörük ,
C Lüke ,
K U Bartz-Schmidt ,
S Grisanti ,
P Szurman
Oct 2009
Read this article at
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
Intraocular ranibizumab (Lucentis, Novartis, Basel Switzerland) is the primary choice in the treatment of neovascular age-related macular degeneration (AMD). Vascular endothelial growth factor (VEGF) is known to be a survival factor for neuronal cells. Therefore, blockage of all VEGF isoforms by ranibizumab could induce retinal dysfunction.